Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JK-1201I in TNBC with Brain Metastases
NCT06586866Phase 2Not yet recruiting
- Sponsor
- JenKem Technology
- Start
- Sep 2024
- Primary completion
- May 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of JK-1201I in triple-negative breast cancer (TNBC), sponsored by JenKem Technology. Primary endpoint: Progression-free Survival according to RECIST 1.1 and RANO-BM at 12 months. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
JK-1201I
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06586866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586866.